Online inquiry

IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3495MR)

This product GTTS-WQ3495MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3495MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3655MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ6481MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ1753MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14035MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ13819MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ4453MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ11812MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14119MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW